
DNAY
Healthcare · Healthcare Equipment & Supplies · $38.4M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2022
EPS trend, 90 days to now · -2.2% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 9, 2023 | Time not confirmed | -0.38 | 0.00 | +100.0% |
| Mar 21, 2023 | Time not confirmed | -0.41 | -0.28 | +32.3% |
| Nov 8, 2022 | After the close | -0.48 | -0.42 | +12.5% |
| Aug 9, 2022 | After the close | -0.51 | -0.50 | +2.0% |
| May 11, 2022 | Before the open | -0.43 | -0.45 | -4.7% |
| Mar 22, 2022 | After the close | -0.37 | -0.43 | -16.2% |
| Nov 9, 2021 | After the close | -0.28 | -0.34 | -21.4% |
| Aug 10, 2021 | After the close | -0.35 | -1.06 | -202.9% |
| Jun 21, 2021 | Before the open | -0.31 | -0.34 | -9.7% |
| Mar 31, 2021 | Time not confirmed | 0.00 | -0.48 | — |
| Mar 31, 2020 | Time not confirmed | 0.00 | -0.26 | — |
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided…